NZ244778A
(en)
*
|
1991-10-21 |
1994-03-25 |
Ortho Pharma Corp |
Peg imidates and protein derivatives thereof
|
US5169627A
(en)
*
|
1991-10-28 |
1992-12-08 |
Mount Sinai School Of Medicine Of The City University Of New York |
Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
|
NZ250375A
(en)
*
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
FI935485A
(fi)
*
|
1992-12-09 |
1994-06-10 |
Ortho Pharma Corp |
PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
|
WO1994015625A1
(fr)
*
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Conjugues de polymere et de facteur viii
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5516703A
(en)
*
|
1993-08-20 |
1996-05-14 |
The University Of Utah |
Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
|
AU7097094A
(en)
*
|
1993-06-01 |
1994-12-20 |
Enzon, Inc. |
Carbohydrate-modified polymer conjugates with erythropoietic activity
|
WO1995000162A1
(fr)
*
|
1993-06-21 |
1995-01-05 |
Enzon, Inc. |
Synthese de peptides conjuges modifies, sur des sites specifiques
|
US6284503B1
(en)
|
1993-08-20 |
2001-09-04 |
University Of Utah Research Foundation |
Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
PT730470E
(pt)
*
|
1993-11-10 |
2002-08-30 |
Enzon Inc |
Conjugados melhorados de interferao-polimero
|
US5446090A
(en)
*
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
US5629384A
(en)
*
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
SE9503380D0
(sv)
*
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
AU778790B2
(en)
*
|
1996-08-02 |
2004-12-23 |
Ortho-Mcneil Pharmaceutical, Inc. |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
EP0964702B1
(fr)
*
|
1996-08-02 |
2006-10-04 |
Ortho-McNeil Pharmaceutical, Inc. |
Polypeptides possedant un polymere soluble dans l'eau a n-terminal lie par covalence simple
|
US6323322B1
(en)
|
1997-04-30 |
2001-11-27 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
JP3688111B2
(ja)
*
|
1998-03-13 |
2005-08-24 |
科学技術振興事業団 |
樹脂固定化ヒドラジドとその誘導体並びにピラゾロン類の固相合成法
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
WO2000064486A2
(fr)
*
|
1999-04-28 |
2000-11-02 |
Vectramed, Inc. |
Conjugues de medicaments polymeres actives par voie enzymatique
|
US6673361B1
(en)
|
1999-05-19 |
2004-01-06 |
Nof Corporation |
Polymer, in vivo degradable material, and use
|
US7608681B2
(en)
|
1999-12-24 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
EP1757701A1
(fr)
|
1999-12-24 |
2007-02-28 |
Genentech, Inc. |
Procédés et compositions pour la prolongation de la demi-vie d'élimination des composés bioactifs
|
AU782580B2
(en)
|
2000-01-10 |
2005-08-11 |
Maxygen, Inc. |
G-CSF conjugates
|
ATE428445T1
(de)
|
2000-02-11 |
2009-05-15 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
YU48703A
(sh)
|
2001-02-27 |
2006-05-25 |
Maxygen Aps |
Novi interferonu beta-slični molekuli
|
WO2004099231A2
(fr)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
BR0214451A
(pt)
*
|
2001-11-20 |
2006-05-30 |
Pharmacia Corp |
conjugados do hormÈnio do crescimento humano quimicamente modificado
|
EP1517710B1
(fr)
|
2002-06-21 |
2011-03-30 |
Novo Nordisk Health Care AG |
Glycoformes du facteur vii pegylees
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
DK1667708T5
(da)
|
2002-12-26 |
2012-11-12 |
Mountain View Pharmaceuticals |
Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro
|
WO2004061094A1
(fr)
|
2002-12-30 |
2004-07-22 |
Gryphon Therapeutics, Inc. |
Composes thioesters et selenoesters hydrosolubles et leurs procedes de production et d'utilisation
|
EP2572732A1
(fr)
|
2003-02-26 |
2013-03-27 |
Nektar Therapeutics |
Conjugués de groupes polymère-facteur VIII
|
MXPA05010411A
(es)
*
|
2003-03-28 |
2006-05-31 |
Biopolymed Inc |
Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen.
|
DE602004025799D1
(de)
|
2003-04-15 |
2010-04-15 |
Glaxosmithkline Llc |
Humane il-18 substitutionsmutanten und deren konjugate
|
AU2004238870B8
(en)
|
2003-05-12 |
2010-04-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
MXPA05012314A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Radical separador para peptido modificado con polietilenglicol.
|
SI1625156T1
(sl)
|
2003-05-12 |
2013-02-28 |
Affymax, Inc. |
Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
|
WO2005012484A2
(fr)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Conjugues anticorps-toxines
|
WO2005014035A2
(fr)
*
|
2003-08-08 |
2005-02-17 |
Novo Nordisk Health Care Ag |
Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
|
CN1867581B
(zh)
|
2003-10-10 |
2012-02-01 |
诺沃挪第克公司 |
Il-21衍生物
|
ES2428358T3
(es)
|
2003-10-17 |
2013-11-07 |
Novo Nordisk A/S |
Terapia de combinación
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
ES2460671T3
(es)
|
2003-12-19 |
2014-05-14 |
F. Hoffmann-La Roche Ag |
Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
|
MXPA06008496A
(es)
|
2004-02-02 |
2007-01-30 |
Ambrx Inc |
Polipeptidos de interferon humano modificados y sus usos.
|
MXPA06014307A
(es)
|
2004-06-08 |
2007-03-12 |
Alza Corp |
Preparacion de conjugados macromoleculares por reaccion de condensacion de cuatro componentes.
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
NZ588839A
(en)
|
2004-07-08 |
2012-09-28 |
Elan Pharm Inc |
Multivalent vla-4 antagonists comprising polyethylene glycol moieties
|
WO2009100255A2
(fr)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Polypeptides leptine modifiés et leurs utilisations
|
EP1814573B1
(fr)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
|
ATE541934T1
(de)
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
BRPI0518661A2
(pt)
|
2004-12-22 |
2008-12-02 |
Ambrx Inc |
mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
|
KR101224781B1
(ko)
|
2004-12-22 |
2013-01-21 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
CA2593682C
(fr)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Facteur de stimulation de colonie de granulocytes glycopegylatees
|
WO2006105993A2
(fr)
|
2005-04-05 |
2006-10-12 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
|
WO2006108052A2
(fr)
|
2005-04-06 |
2006-10-12 |
Genzyme Corporation |
Ciblage de glycoproteines therapeutiques
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US8324159B2
(en)
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
EP1893229B1
(fr)
|
2005-06-03 |
2011-10-19 |
Ambrx, Inc. |
Molecules d'interferons humains ameliorees et utilisations de celles-ci
|
EP1893632B1
(fr)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Reduction et derivation séléctives de proteines facteur vii comprenant au moins une cysteine non native
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
WO2007056191A2
(fr)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Purification de sucre de nucleotide en utilisant des membranes
|
PT2339014E
(pt)
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Métodos e composições compreendendo aminoácidos não-naturais
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
KR20080108147A
(ko)
|
2006-03-31 |
2008-12-11 |
백스터 인터내셔널 인코포레이티드 |
페질화된 인자 viii
|
CN104593348A
(zh)
|
2006-05-24 |
2015-05-06 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内半寿期的因子ix类似物
|
JP2009544327A
(ja)
|
2006-07-21 |
2009-12-17 |
ノヴォ ノルディスク アー/エス |
O−結合型グリコシル化配列によるペプチドのグリコシル化
|
EP2059527B1
(fr)
|
2006-09-01 |
2014-12-03 |
Novo Nordisk Health Care AG |
Glycoprotéines modifiées
|
US8420792B2
(en)
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
CA2662753C
(fr)
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Arnt suppresseur hybride pour cellules de vertebres
|
CN106008699A
(zh)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
EP2054521A4
(fr)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Méthodes de purification de conjugués de polypeptides
|
CN103804489A
(zh)
|
2006-12-15 |
2014-05-21 |
巴克斯特国际公司 |
具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
|
PL2121713T3
(pl)
|
2007-01-18 |
2013-11-29 |
Genzyme Corp |
Oligosacharydy zawierające grupę aminooksylową oraz ich koniugaty
|
EP2118127A4
(fr)
|
2007-01-31 |
2010-12-01 |
Affymax Inc |
Groupements de liaison à base d'azote destinés à attacher des groupements modificateurs à des polypeptides et autres macromolécules
|
EP2068909B1
(fr)
|
2007-03-30 |
2012-04-25 |
Ambrx, Inc. |
Polypeptides fgf-21 modifies, et leurs utilisations
|
KR20150064246A
(ko)
|
2007-04-03 |
2015-06-10 |
바이오제너릭스 게엠베하 |
글리코페길화 g―csf를 이용하는 치료 방법
|
AU2008247815B2
(en)
|
2007-05-02 |
2012-09-06 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
JP5547083B2
(ja)
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
MX348657B
(es)
|
2008-09-26 |
2017-06-21 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
ITRM20080551A1
(it)
*
|
2008-10-15 |
2010-04-16 |
Univ Catania |
Derivati anfifilici del poliossietilenglicole (peg), procedimento di preparazione e loro usi nella preparazione di sistemi farmaceutici.
|
KR20100052730A
(ko)
*
|
2008-11-11 |
2010-05-20 |
한국유니온제약 주식회사 |
생체적합성 고분자와 결합한 신규한 에리스로포이에틴 접합체
|
EP3608330B1
(fr)
|
2008-12-16 |
2022-11-09 |
Genzyme Corporation |
Intermédiaires synthétiques utiles dans la préparation des conjugués oliogosaccharide-protéine
|
WO2010080720A2
(fr)
*
|
2009-01-12 |
2010-07-15 |
Nektar Therapeutics |
Conjugués d'une fraction enzymatique lysosomale et polymère soluble dans l'eau
|
NZ597600A
(en)
*
|
2009-07-27 |
2014-05-30 |
Lipoxen Technologies Ltd |
Glycopolysialylation of non-blood coagulation proteins
|
TWI537006B
(zh)
|
2009-07-27 |
2016-06-11 |
巴克斯歐塔公司 |
凝血蛋白接合物
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
RU2744370C2
(ru)
*
|
2009-07-27 |
2021-03-05 |
Баксалта Инкорпорейтед |
Конъюгаты белков свертывания крови
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
US8945575B2
(en)
*
|
2009-12-01 |
2015-02-03 |
Trustees Of Boston University |
Treatment of IgE-mediated disease
|
AU2010341516B2
(en)
|
2009-12-21 |
2014-01-16 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
CA2784800A1
(fr)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Polypeptides d'hormone de croissance porcine modifiee et leurs utilisations
|
AU2011222883B2
(en)
|
2010-03-05 |
2016-05-26 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
EP2569331A1
(fr)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptides inhibiteurs de vla4
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
SG10201506443TA
(en)
|
2010-08-17 |
2015-10-29 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
CA2822591C
(fr)
|
2010-12-22 |
2020-12-29 |
Baxter International Inc. |
Materiels et methodes pour la conjugaison d'un derive d'acide gras soluble dans l'eau a une proteine
|
BR112014000055A2
(pt)
|
2011-07-01 |
2017-06-13 |
Bayer Ip Gmbh |
polipeptídeos de fusão de relaxina e usos dos mesmos
|
CN103747807B
(zh)
|
2011-07-05 |
2016-12-07 |
比奥阿赛斯技术有限公司 |
P97‑抗体缀合物和使用方法
|
US20150224205A1
(en)
*
|
2012-03-16 |
2015-08-13 |
Belrose Pharma, Inc. |
Polymeric conjugates of c-1 inhibitors
|
SG11201408161RA
(en)
|
2012-06-08 |
2015-01-29 |
Sutro Biopharma Inc |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
CA2880162C
(fr)
|
2012-07-31 |
2023-04-04 |
Bioasis Technologies, Inc. |
Proteines de maladie de stockage lysosomal dephosphorylees et leurs procedes d'utilisation
|
SI3584255T1
(sl)
|
2012-08-31 |
2022-05-31 |
Sutro Biopharma, Inc |
Modificirane aminokisline, ki vsebujejo azido skupino
|
EP2916835A4
(fr)
|
2012-11-12 |
2016-07-27 |
Redwood Bioscience Inc |
Composés et procédés pour produire un conjugué
|
KR20150085064A
(ko)
|
2012-11-16 |
2015-07-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
단백질 화학적 변형을 위한 피크테 스펭글러 결합
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
p97のフラグメントおよびその使用
|
EA021610B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Жидкое противовирусное лекарственное средство
|
EA023323B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
EA021643B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
EA022617B1
(ru)
*
|
2013-03-28 |
2016-02-29 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
EA023360B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
WO2015006555A2
(fr)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
AU2014354643B2
(en)
|
2013-11-27 |
2020-03-05 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
LT3412302T
(lt)
|
2014-10-24 |
2021-07-26 |
Bristol-Myers Squibb Company |
Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
|
CN107949565A
(zh)
*
|
2015-06-11 |
2018-04-20 |
安姆生物制药有限责任公司 |
聚乙二醇化粒细胞集落刺激因子(gcsf)
|
ES2826827T3
(es)
|
2015-06-15 |
2021-05-19 |
Angiochem Inc |
Métodos para el tratamiento de carcinomatosis leptomeníngea
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
AU2018298224A1
(en)
|
2017-07-07 |
2020-01-30 |
Symic Ip, Llc |
Synthetic bioconjugates
|
US11492493B2
(en)
|
2017-12-26 |
2022-11-08 |
Becton, Dickinson And Company |
Deep ultraviolet-excitable water-solvated polymeric dyes
|
EP3775052B1
(fr)
|
2018-03-30 |
2024-06-05 |
Becton, Dickinson and Company |
Colorants polymères hydrosolubles portant des chromophores latéraux
|
WO2020023300A1
(fr)
|
2018-07-22 |
2020-01-30 |
Bioasis Technologies, Inc. |
Traitement de métastases lymphatiques
|
CA3111576A1
(fr)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Conjugues polypeptidiques d'interleukine-2 et leurs utilisations
|
EP3867265A1
(fr)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Conjugués polypeptidiques d'interleukine-10, dimères de ceux-ci et leurs utilisations
|
CA3128081A1
(fr)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Contenant de compositions, procedes et utilisations de conjugues anticorps-agonistes tlr
|
KR20220151202A
(ko)
|
2020-03-11 |
2022-11-14 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
AU2022249223A1
(en)
|
2021-04-03 |
2023-10-12 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
EP4155349A1
(fr)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Colorants absorbants jaunes verts solubles dans l'eau
|
WO2024007016A2
(fr)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Nouveaux colorants fluorescents et polymères issus de dérivés de dihydrophenanthrène
|
WO2024044327A1
(fr)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Monomères dhnt et colorants polymères ayant des propriétés photophysiques modifiées
|